Regeneron (REGN) Pharmaceuticals announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at the American Society of Hematology, ASH, 2025 Annual Meeting, taking place from December 6-9 in Orlando, FL. Presentations highlight the next wave of potential novel approaches across a range of blood cancers and disorders. Progress on the odronextamab development program will be featured in six abstracts including an oral presentation on the first results of odronextamab plus chemotherapy from OLYMPIA-3 in previously untreated diffuse large B-cell lymphoma. Other presentations include the first results from Part 1 of two Phase 3 trials evaluating odronextamab in follicular lymphoma – odronextamab plus chemotherapy in frontline FL as well as odronextamab plus lenalidomide in R/R FL.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron initiated with a Sector Perform at Scotiabank
- Regeneron: Strong Buy Rating Backed by Robust Business and Promising Oncology Developments
- Regeneron’s Innovative Anticoagulation Advancements and Market Potential Drive Buy Rating
- Regeneron treatment of pulmonary arterial hypertension granted orphan status
- Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study